DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for peeling skin syndrome type A — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePeeling skin syndrome type A maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for peeling skin syndrome type a is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 1997 case report described a 34-year-old man with a lifelong history of peeling skin confined mainly to his hands and feet, worsened by water, perspiration, heat, or friction. Histology showed a split above the granular layer with no inflammation. The authors called this a new variant, acral peeling skin syndrome, because all previously published reports described widespread peeling. A 2010 review of peeling skin syndrome (PSS) stated that type A is the non-inflammatory variant, presenting with asymptomatic continuous peeling from the neck, trunk, back, and extremities, with friction as an aggravating factor and no seasonal variation. Histopathology in that review showed hyperkeratosis and splitting between the granular layer and stratum corneum. The 2010 review also stated plainly that no treatment for this disorder has been found to be effective so far.
A 2023 Chinese expert consensus on chemical peels covered their use for various skin diseases and photoaging, but it did not mention peeling skin syndrome at all, and no abstract provided any data on a drug or intervention tested in PSS type A. The only patient-level detail comes from the single 1997 case, and no controlled trial, no survival data, no response rates, and no sample size beyond that single patient exist in these abstracts.
What is still missing is any funded clinical trial, any validated outcome measure for skin peeling in this disease, and any attempt to stratify patients by genetic subtype or inflammatory status. Without those, the claim that no treatment is effective remains based on a single case and expert opinion from 2010.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Dermatology · 1997 · 30 citations
Acral peeling skin syndrome
AbstractA young man presented to our department with a lifelong history of localized peeling skin of his acral surfaces, especially after exposure to heat, humidity, and/or friction. A histological examination revealed a split above the granular layer without inflammatory response. Only a few reports of peeling skin syndrome have been published and they all describe widespread peeling. Peeling skin syndrome localized to the acral surfaces represents a new variant. <h3>Report of a Case.</h3> A 34-year-old white man was referred to us for possible epidermolysis bullosa. He reported a lifelong history of peeling skin, mainly on both surfaces of his hands and feet, that worsened with exposure to water, perspiration, heat, or friction. Rarely, peeling would occur higher up on his arms and legs. He also reported discreet areas that were callused and pruritic. After soaking his hands and feet in water for 15 minutes and lightly rubbing the skin, he
AbstractA young man presented to our department with a lifelong history of localized peeling skin of his acral surfaces, especially after exposure to heat, humidity, and/or friction. A histological examination revealed a split above the granular layer without inflammatory response. Only a few reports of peeling skin syndrome have been published and they all describe widespread peeling. Peeling skin syndrome localized to the acral surfaces represents a new variant. <h3>Report of a Case.</h3> A 34-year-old white man was referred to us for possible epidermolysis bullosa. He reported a lifelong history of peeling skin, mainly on both surfaces of his hands and feet, that worsened with exposure to water, perspiration, heat, or friction. Rarely, peeling would occur higher up on his arms and legs. He also reported discreet areas that were callused and pruritic. After soaking his hands and feet in water for 15 minutes and lightly rubbing the skin, he
AbstractPeeling Skin Syndrome (PSS) is a rare genodermatoses characterized by asymptomatic, localized or generalized, continuous exfoliation of the stratum corneum; it may present at birth or in adulthood. We describe a patient having the type A non-inflammatory variant of PSS showing asymptomatic and continuous skin peeling from the neck, trunk, back, and extremities. Friction appeared to be an aggravating factor, but there was no seasonal variation. Histopathology in this condition reveals hyperkeratosis and splitting of the epidermis between the granular layer and the stratum corneum. No treatment for this disorder has been found to be effective so far.
International Journal of Dermatology and Venereology · 2023 · 0 citations · open access
Expert Consensus on the Clinical Application of Chemical Peels in China (2022) #
AbstractChemical peels are widely used to treat various skin diseases and photoaging. Their rational, effective, and safe use has become an important issue in clinical practice. To standardize the clinical use of chemical peels, a group of experts developed this consensus based on the latest research and discussions. This consensus provides specific guidance to clinicians on chemical peels with respect to their classification, peeling agents, mechanisms, indications, contraindications, peeling techniques, and complications.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
